Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 Jul;92(7):775-84.

[5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II]

[Article in Japanese]
Affiliations
  • PMID: 1886590
Clinical Trial

[5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II]

[Article in Japanese]
N Takahashi. Nihon Geka Gakkai Zasshi. 1991 Jul.

Abstract

A preferable route for administration of anti-cancer drugs together with angiotensin-II (AT-II) was examined by measuring the tissue concentration of drugs in resected specimens. Twenty five patients with gastric cancer were randomly divided into five groups, and 5-FU (250 mg) was given with or without AT-II intraoperatively. Group A; i.v. 5-FU alone (n = 5), Group B; i.v. 5-FU with AT-II (n = 5), Group C; i.a. 5-FU alone (n = 5), Group D; i.a. 5-FU with i.v. AT-II (n = 5) and Group E; i.a. 5-FU with AT-II (n = 5). 5-FU level in regional lymph nodes was statistically higher in Group D compared to other groups, while in tumor tissues it was markedly higher in Group E. The ratio of 5-FU level in tumor tissues to normal tissues (T/N) was higher in Groups D and E. In patients with advanced malignancies, response rates were 17% in i.v. anti-cancer drugs with AT-II group, 41% in i.a. anti-cancer drugs with i.v. AT-II group and 24% in i.a. anti-cancer drugs with AT-II group. Median survival time for each group were 6.3 months, 9.6 months and 14.2 months, respectively. It is concluded that intra-arterial infusion chemotherapy together with AT-II can be an effective treatment for advanced malignancies.

PubMed Disclaimer

MeSH terms

LinkOut - more resources